Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for aTYR PHARMA (ATYR) over the last 5 years, with Q3 2025 value amounting to -$0.26.

  • aTYR PHARMA's EPS (Weighted Average and Diluted) fell 1304.35% to -$0.26 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.82, marking a year-over-year increase of 1276.6%. This contributed to the annual value of -$0.91 for FY2024, which is 270.98% up from last year.
  • According to the latest figures from Q3 2025, aTYR PHARMA's EPS (Weighted Average and Diluted) is -$0.26, which was down 1304.35% from -$0.22 recorded in Q2 2025.
  • Over the past 5 years, aTYR PHARMA's EPS (Weighted Average and Diluted) peaked at -$0.17 during Q1 2025, and registered a low of -$0.46 during Q3 2022.
  • For the 4-year period, aTYR PHARMA's EPS (Weighted Average and Diluted) averaged around -$0.26, with its median value being -$0.23 (2024).
  • Per our database at Business Quant, aTYR PHARMA's EPS (Weighted Average and Diluted) soared by 5652.17% in 2023 and then tumbled by 1500.0% in 2024.
  • Over the past 4 years, aTYR PHARMA's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.26 in 2022, then increased by 3.85% to -$0.25 in 2023, then increased by 14.79% to -$0.21 in 2024, then dropped by 22.05% to -$0.26 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.26 for Q3 2025, versus -$0.22 for Q2 2025 and -$0.17 for Q1 2025.